247 related articles for article (PubMed ID: 22481060)
41. Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase.
Saif MW; Black G; Roy S; Bell D; Russo S; Eloubeidi MA; Steg A; Johnson MR; Zelterman D; Diasio RB
Cancer J; 2007; 13(4):247-56. PubMed ID: 17762760
[TBL] [Abstract][Full Text] [Related]
42. Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy.
Toi M; Ikeda T; Akiyama F; Kurosumi M; Tsuda H; Sakamoto G; Abe O
Int J Oncol; 2007 Oct; 31(4):899-906. PubMed ID: 17786323
[TBL] [Abstract][Full Text] [Related]
43. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
Ouchi KF; Yanagisawa M; Sekiguchi F; Tanaka Y
Cancer Chemother Pharmacol; 2006 May; 57(5):693-702. PubMed ID: 16362295
[TBL] [Abstract][Full Text] [Related]
44. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
Chefrour M; Milano G; Formento P; Giacometti S; Denden A; Renée N; Iliadis A; Fischel JL; Ciccolini J
Fundam Clin Pharmacol; 2012 Aug; 26(4):530-7. PubMed ID: 21623901
[TBL] [Abstract][Full Text] [Related]
45. Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
Michalaki V; Fotiou S; Gennatas S; Gennatas C
Anticancer Res; 2010 Jul; 30(7):3051-4. PubMed ID: 20683054
[TBL] [Abstract][Full Text] [Related]
46. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
47. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma.
Lee J; Im YH; Cho EY; Hong YS; Lee HR; Kim HS; Kim MJ; Kim K; Kang WK; Park K; Shim YM
Cancer Chemother Pharmacol; 2008 Jun; 62(1):77-84. PubMed ID: 17762932
[TBL] [Abstract][Full Text] [Related]
48. [Thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in soft-tissue sarcoma versus capecitabine potential].
Stepanova EV; Bokhian BIu; Petrovichev NN; Lichinitzer MR
Vopr Onkol; 2005; 51(3):314-6. PubMed ID: 16279094
[TBL] [Abstract][Full Text] [Related]
49. Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults.
Patel A; Pluim T; Helms A; Bauer A; Tuttle RM; Francis GL
Cancer Chemother Pharmacol; 2004 May; 53(5):409-14. PubMed ID: 15132128
[TBL] [Abstract][Full Text] [Related]
50. Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.
Uchida K; Danenberg PV; Danenberg KD; Grem JL
BMC Cancer; 2008 Dec; 8():386. PubMed ID: 19105824
[TBL] [Abstract][Full Text] [Related]
51. Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer.
Jensen SA; Vainer B; Witton CJ; Jørgensen JT; Sørensen JB
Acta Oncol; 2008; 47(6):1054-61. PubMed ID: 18607850
[TBL] [Abstract][Full Text] [Related]
52. Thymidine phosphorylase mRNA level predicts survival of patients with advanced oropharyngeal cancer.
Ijuin T; Nibu K; Doi K; Inoue H; Saitoh M; Ohtsuki N; Makino K; Amatsu M
Acta Otolaryngol; 2007 Mar; 127(3):305-11. PubMed ID: 17364369
[TBL] [Abstract][Full Text] [Related]
53. Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer.
Kamal AH; Camacho F; Anderson R; Wei W; Balkrishnan R; Kimmick G
Breast Cancer Res Treat; 2012 Jul; 134(1):371-8. PubMed ID: 22460617
[TBL] [Abstract][Full Text] [Related]
54. Prognostic predictors in breast cancer patients with postoperative 5-fluorouracil-based chemotherapy.
Hakamada Y; Tsuchida A; Arima M; Kubouchi T; Tokita H; Ota D; Kaise H; Aoki T; Kusama M; Aoki T
Int J Mol Med; 2005 Aug; 16(2):309-14. PubMed ID: 16012767
[TBL] [Abstract][Full Text] [Related]
55. Prognostic impact of thymidine phosphorylase expression in breast cancer--comparison of microarray and immunohistochemical data.
Ruckhäberle E; Karn T; Engels K; Turley H; Hanker L; Müller V; Schmidt M; Ahr A; Gaetje R; Holtrich U; Kaufmann M; Rody A
Eur J Cancer; 2010 Feb; 46(3):549-57. PubMed ID: 20022486
[TBL] [Abstract][Full Text] [Related]
56. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
Hortobagyi GN; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Lerzo GL; Pivot XB; Hurtado de Mendoza F; Xu B; Vahdat LT; Peck RA; Mukhopadhyay P; Roché HH
Breast Cancer Res Treat; 2010 Jul; 122(2):409-18. PubMed ID: 20454927
[TBL] [Abstract][Full Text] [Related]
57. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome.
Saif MW; Eloubeidi MA; Russo S; Steg A; Thornton J; Fiveash J; Carpenter M; Blanquicett C; Diasio RB; Johnson MR
J Clin Oncol; 2005 Dec; 23(34):8679-87. PubMed ID: 16314628
[TBL] [Abstract][Full Text] [Related]
58. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
Lee SS; Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Kim WK; Lee JS; Kang YK
Jpn J Clin Oncol; 2007 Jan; 37(1):30-7. PubMed ID: 17272321
[TBL] [Abstract][Full Text] [Related]
59. The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma.
Saito H; Tsujitani S; Oka S; Kondo A; Ikeguchi M; Maeta M; Kaibara N
Br J Cancer; 1999 Oct; 81(3):484-9. PubMed ID: 10507774
[TBL] [Abstract][Full Text] [Related]
60. beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial.
Cullen KJ; Schumaker L; Nikitakis N; Goloubeva O; Tan M; Sarlis NJ; Haddad RI; Posner MR
J Clin Oncol; 2009 Dec; 27(36):6222-8. PubMed ID: 19917838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
